Chester County News and Community Website
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ATI-052, a bispecific …
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial Read More
WAYNE, PA — Cagent Vascular has announced the enrollment of the first patient in its groundbreaking Serranator vs. POBA OCT Study. This innovative clinical trial aims to evaluate the benefits …
Cagent Vascular Launches Landmark Study on Serration Angioplasty Technology Read More
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) unveiled promising results from its Open-Label Extension (OLE) study evaluating ZYN002, a potential treatment for Fragile X syndrome (FXS). The …
Harmony Biosciences Presents Positive Data on ZYN002 for Fragile X Syndrome Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the presentation of its investigational therapy QTORIN™ rapamycin 3.9% anhydrous gel for microcystic lymphatic malformations (microcystic LMs) at the 15th World …
Palvella Therapeutics Showcases Progress on QTORIN Rapamycin Gel for Rare Genetic Disorder Read More
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the dosing of the first patient in its Phase 1 clinical trial of CT-95, a bispecific antibody designed to target …
Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers Read More
WILMINGTON, DE — New data from the PURSUIT Phase IIb trial reveal AstraZeneca‘s investigational oral PCSK9 inhibitor, AZD0780, delivers significant reductions in LDL cholesterol (LDL-C) when combined with standard-of-care statin …
AstraZeneca’s AZD0780 Shows Promising Results in Cholesterol-Lowering Clinical Trial Read More
SPRING HOUSE, PA — Johnson & Johnson has announced promising results from its Phase 3b APEX trial for TREMFYA® (guselkumab), revealing its effectiveness in treating active psoriatic arthritis (PsA). The …
Johnson & Johnson’s TREMFYA Demonstrates Significant Benefits in Psoriatic Arthritis Study Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a key milestone in its ACESOT-1051 clinical trial, as the first patient with HPV-positive (HPV+) head and neck squamous cell carcinoma (HNSCC) …
Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing Read More SPRING HOUSE, PA — Johnson & Johnson presented new data on its investigational treatment, nipocalimab, at the 2025 American Academy of Neurology (AAN) Annual Meeting, providing insight into its potential to …
Johnson & Johnson Showcases Promising Data on Nipocalimab for gMG at AAN Annual Meeting Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has shared promising preliminary results from its Ringer™ PBC IDE study, featured in a presentation at the CTO Plus Conference in New York. The …
Teleflex Reports Promising Preliminary Results for Ringer PBC Study Read More